Search company, investor...

Predict your next investment

New Science Ventures company logo
Venture Capital
FINANCE | Investment Firms & Funds
newscienceventures.com

Investments

138

Portfolio Exits

22

Funds

10

About New Science Ventures

New Science Ventures (NSV) is a venture capital firm which invests in both early and late-stage companies using scientific approaches to address significant, unmet needs in Life Sciences (pharmaceuticals, biologics, medical devices, and diagnostics) and Information Technology (high-performance semiconductors, cellular infrastructure, sensor networks, enterprise software, and storage) sectors.

Headquarters Location

500 West Putnam Avenue, Suite 400

Greenwich, Connecticut, 06830,

United States

212-688-5100

Want to inform investors similar to New Science Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest New Science Ventures News

Novadip Biosciences S.A.. (11/3/22). "Press Release: Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company...

Nov 9, 2022

Region   > Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures > Equity Funding led by CR-CP Life Science Fund, New Science Ventures, Fund+ and SRIW Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding. The funding will accelerate the clinical development of two of Novadip’s investigational adipose stem cell (ASC)-derived tissue regeneration products: NVD-X3, an allogeneic therapeutic that can provide accelerated, durable bone union in spinal fusion procedures and non-healing fractures, and NVD-003, an autologous bone engraftment product designed to provide a single treatment cure for patients with critical size bone defects such as congenital pseudoarthrosis of the tibia (CPT). The EUR 40 million financing is comprised of EUR 24 million in new equity and EUR 16 million in non-dilutive financing mainly by the Walloon Region. CR-CP Life Science Fund (China) joined existing investors, including New Science Ventures (US), Fund+, SRIW Life Sciences, VIVES Louvain Technology Fund, InvestSud, family offices and private investors, such as Pierre Drion and Olivier van der Rest, to support the equity round. “This financing milestone is a recognition by our committed group of existing investors of the clinical benefits and broad market opportunities provided by our 3M³ tissue regeneration technology platform,” said Denis Dufrane, MD, PhD, CEO and Co-founder of Novadip Biosciences. “With this funding we will advance a new class of therapeutics that offer curative hope for patients suffering from large bone defects and enable accelerated healing of common orthopedic conditions such as radius fracture, spinal fusion.” Novadip’s 3M³ platform is a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly specific growth factors and miRNAs to mimic the physiology of natural tissue healing. The platform supports three distinct therapeutic programs: > 3MAUTO: autologous ASC products that provide one-time curative treatment to achieve long-term union and stability of critical size bone defects > 3MALLO: “off-the-shelf” allogeneic matrix products to provide accelerated, stable bone union in 90 percent of bone engraftment procedures – a $7 billion addressable market, and > 3MEXO: allogeneic exosome products that can repair tissue following surgical resection of solid tumors, such as osteosarcoma, melanoma, glioblastoma. “We welcome the expanded support of our international investors, all of whom appreciate the immense potential of the 3M3 technology platform to deliver best-in-class tissue regeneration products that disrupt the standard of care in the US, EU and Asia,” said Eric P. Pâques, PhD, Chairman of the Novadip Biosciences Board of Directors. “We have been enormously impressed with the progress the Novadip team has achieved in advancing the 3MAUTO and 3MALLO programs into clinical studies. Looking ahead, it is clear that Novadip’s therapeutic programs can be hugely important for patients, and we look forward to supporting these dedicated individuals as they work to cultivate the clinical promise of the 3M3 technology platform across multiple high opportunity markets.” About NVD-X3 for Spinal Fusion and Bone Non-Union Applications The risk of bone non-union following fracture is greater than 50% across all bones due to fracture severity, co-morbidities (diabetes, obesity, smoking and other conditions) and medication use1. Additionally, more than 600,000 spine fusion procedures are performed annually. Together, these indications represent a peak sales opportunity for Novadip of $2.2 billion. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing?. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics?. A favorable COGS profile supports broad distribution and expanded patient access. Preclinical studies demonstrate that NVD-X3 offers superior bioactivity without the undesirable bone formation/resorption and inflammation observed with currently marketed bone engraftment products?. Novadip plans to initiate a Phase 1/2 clinical trial for NVD-X3 in spine fusion and bone non-union procedures in Europe by the end of 2022. About NVD-003 and CPT Congenital pseudarthrosis of the tibia (CPT) is a rare pediatric bone condition occurring in one in 150,000 births. Children with CPT endure a high disease burden, including frequent fractures, loss of mobility, and potential amputation. The current standard of care - surgery with autologous bone graft - is associated with poor long-term outcomes, including high risk of chronic pain, infection, blood loss requiring transfusion, and persistent risk of amputation. Novadip is developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility? in patients with CPT. The favorable safety profile and potential clinical utility of NVD-003 for promoting healthy and durable bone formation is supported by clinical data from more than 50 adult and pediatric patients with non-healing fractures of the lower limb, bone non-union (BNU), obtained in Phase 1b/2a clinical trials and compassionate use. The active cells in NVD-003 autologous graft helped achieve durable union in critical size bone fractures with up to 5 years follow-up data. These results de-risk the company’s clinical development program for CPT and support future discussions with drug regulatory agencies about the design of late-stage pivotal trials to support eventual product registration. Novadip will initiate a Phase 1b/2a clinical trials in CPT patients between two and eight years of age in the US and EU end of 2022.? NVD-003 has received orphan drug and rare pediatric disease designations for accelerated approval from the US Food and Drug Administration (FDA). If NVD-003 is approved by the FDA, Novadip is eligible to receive a priority review voucher that could provide more than $100 million revenue. About Novadip Biosciences Novadip Biosciences is a clinical stage company developing best in class tissue regeneration therapies to elevate the standard of care for critical size bone defects, common orthopedic conditions, and cancer. Its unique 3M³ tissue regeneration technology platform has the potential to generate an array of product candidates to address hard and soft tissue reconstruction for patients with limited or no treatment options. Co-Founded in 2013 by Denis Dufrane, MD, PhD, Novadip is headquartered in Mont Saint-Guibert, Belgium. For more information, visit https://www.novadip.com/. __________________________ 1 Zura et al. Epidemiology of Fracture Nonunion in 18 Human Bones. JAMA Surg. 2016;151(11):e162775. November 16, 2016? Contacts

New Science Ventures Investments

138 Investments

New Science Ventures has made 138 investments. Their latest investment was in Novadip Biosciences as part of their Series B - II on November 11, 2022.

CBI Logo

New Science Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/4/2022

Series B - II

Novadip Biosciences

$23.69M

No

2

7/13/2022

Seed VC

Morrow Eyewear

$10M

Yes

3

3/4/2022

Series F

Vascular Therapies

$25M

No

2

2/14/2022

Unattributed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

1/30/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/4/2022

7/13/2022

3/4/2022

2/14/2022

1/30/2022

Round

Series B - II

Seed VC

Series F

Unattributed VC - II

Series B

Company

Novadip Biosciences

Morrow Eyewear

Vascular Therapies

Subscribe to see more

Subscribe to see more

Amount

$23.69M

$10M

$25M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

2

10

10

New Science Ventures Portfolio Exits

22 Portfolio Exits

New Science Ventures has 22 portfolio exits. Their latest portfolio exit was BrightBytes on October 11, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/11/2022

Acquired

$99M

1

10/21/2021

IPO

$99M

Public

20

7/19/2021

IPO

$99M

Public

1

1/26/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/12/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/11/2022

10/21/2021

7/19/2021

1/26/2021

1/12/2021

Exit

Acquired

IPO

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

20

1

10

10

New Science Ventures Fund History

10 Fund Histories

New Science Ventures has 10 funds, including NSV 2020 Preferred LP Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/13/2020

NSV 2020 Preferred LP Fund

Early-Stage Venture Capital

Open

$4.89M

1

2/15/2019

NSV 2019 Opportunities Fund

Early-Stage Venture Capital

Open

$5.7M

2

1/31/2018

NSV 2018 Opportunities Fund

Early-Stage Venture Capital

Closed

$26.79M

1

1/31/2018

NSV 2018 New Horizons Fund

$99M

10

2/15/2017

NSV 2017 Opportunities Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

2/13/2020

2/15/2019

1/31/2018

1/31/2018

2/15/2017

Fund

NSV 2020 Preferred LP Fund

NSV 2019 Opportunities Fund

NSV 2018 Opportunities Fund

NSV 2018 New Horizons Fund

NSV 2017 Opportunities Fund LP

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Status

Open

Open

Closed

Subscribe to see more

Amount

$4.89M

$5.7M

$26.79M

$99M

$99M

Sources

1

2

1

10

10

New Science Ventures Team

3 Team Members

New Science Ventures has 3 team members, including current Founder, Managing Partner, Somu Subramaniam.

Name

Work History

Title

Status

Somu Subramaniam

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Somu Subramaniam

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Partner

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.